Shots:Shots: AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated P-III study to assess Farxiga (dapagliflozin) + SOC vs PBO in patients hospitalized with COVID-19 having a risk of developing serious complications like organ failure The primary outcome of the study is time to the first occurrence of death from any cause or new/worsened […]Read More
